Title |
Trends and advances in tumor immunology and lung cancer immunotherapy
|
---|---|
Published in |
Journal of Experimental & Clinical Cancer Research, September 2016
|
DOI | 10.1186/s13046-016-0439-3 |
Pubmed ID | |
Authors |
Mohanad Aldarouish, Cailian Wang |
Abstract |
Among several types of tumor, lung cancer is considered one of the most fatal and still the main cause of cancer-related deaths. Although chemotherapeutic agents can improve survival and quality of life compared with symptomatic treatment, cancers usually still progress after chemotherapy and are often aggravated by serious side effects. In the last few years there has been a growing interest in immunotherapy for lung cancer based on promising preliminary results in achieving meaningful and durable treatments responses with minimal manageable toxicity. This article is divided into two parts, the first part discusses the role of human immune system in controlling and eradicating cancer and the mechanisms of immune response evasion by tumor. The second part reviews the recent progress made in immunotherapy for lung cancer with results from trials evaluating therapeutic vaccines in addition to immune checkpoint blockade, specifically cytotoxic T lymphocyte associated protein 4, programmed death receptor 1 pathway, using monoclonal antibodies. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Unknown | 124 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 18 | 14% |
Student > Master | 16 | 13% |
Student > Bachelor | 15 | 12% |
Researcher | 13 | 10% |
Other | 7 | 6% |
Other | 19 | 15% |
Unknown | 37 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 34 | 27% |
Biochemistry, Genetics and Molecular Biology | 20 | 16% |
Immunology and Microbiology | 10 | 8% |
Agricultural and Biological Sciences | 9 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
Other | 7 | 6% |
Unknown | 38 | 30% |